PDF(Pubmed)
Abstract：
UNASSIGNED: Mitogen-activated protein kinase kinase (MEK) inhibitors are targeted anticancer agents that are prescribed to treat a broad range of cancers. Despite their strong efficacy profile, MEK inhibitors have been associated with ocular toxicities, most notably, self-limited serous detachments of the neurosensory retina. In this report, we outline 3 cases of a rarely documented toxicity, MEK inhibitor-associated ocular hypertension.
UNASSIGNED: In the first case, a 69-year-old female with metastatic cholangiocarcinoma presented with an intraocular pressure (IOP) of 25 mm Hg right eye (OD) and 27 mm Hg left eye (OS) 2 months after starting trametinib therapy. Similarly, in the second case, a 26-year-old female with Langerhans cell histiocytosis presented with an elevated IOP of 24 mm Hg bilaterally (OU) 13 months after beginning treatment with an investigational MEK inhibitor. In the third case, a 46-year-old male with Langerhans cell histiocytosis presented with a new onset of elevated IOP of 24 mm Hg 21 days after initiating treatment with cobimetinib. All 3 patients\' IOP returned to normal following dorzolamide/timolol administration and continued their cancer therapy.
UNASSIGNED: This report presents 3 cases of elevated IOP in patients taking three distinct MEK inhibitors which would suggest that IOP-elevating effects exist across the class of MEK inhibitors. All 3 patients had a satisfactory response to topical pressure-lowering drops while continuing their life-preserving MEK inhibitor drug dose, indicating that discontinuation of therapy may not be necessary. Due to the increasing use of MEK inhibitors, it is important that ophthalmologists familiarize themselves with the broad range of potential adverse ocular effects of MEK inhibitors.
UNASSIGNED: In the first case, a 69-year-old female with metastatic cholangiocarcinoma presented with an intraocular pressure (IOP) of 25 mm Hg right eye (OD) and 27 mm Hg left eye (OS) 2 months after starting trametinib therapy. Similarly, in the second case, a 26-year-old female with Langerhans cell histiocytosis presented with an elevated IOP of 24 mm Hg bilaterally (OU) 13 months after beginning treatment with an investigational MEK inhibitor. In the third case, a 46-year-old male with Langerhans cell histiocytosis presented with a new onset of elevated IOP of 24 mm Hg 21 days after initiating treatment with cobimetinib. All 3 patients\' IOP returned to normal following dorzolamide/timolol administration and continued their cancer therapy.
UNASSIGNED: This report presents 3 cases of elevated IOP in patients taking three distinct MEK inhibitors which would suggest that IOP-elevating effects exist across the class of MEK inhibitors. All 3 patients had a satisfactory response to topical pressure-lowering drops while continuing their life-preserving MEK inhibitor drug dose, indicating that discontinuation of therapy may not be necessary. Due to the increasing use of MEK inhibitors, it is important that ophthalmologists familiarize themselves with the broad range of potential adverse ocular effects of MEK inhibitors.
摘要：
丝裂原活化的蛋白激酶激酶(MEK)抑制剂是用于治疗多种癌症的靶向抗癌剂。尽管它们的功效很强，MEK抑制剂与眼部毒性有关，最值得注意的是,神经感觉视网膜的自我限制的浆液性脱离。在这份报告中,我们概述了3例罕见的毒性，MEK抑制剂相关的高眼压。
■在第一种情况下，1例69岁女性转移性胆管癌患者,在开始曲美替尼治疗2个月后,其右眼眼压(OD)为25mmHg,左眼眼压(OS)为27mmHg.同样，在第二种情况下，1例26岁女性朗格汉斯细胞组织细胞增生症患者,在开始使用研究性MEK抑制剂治疗13个月后,双侧眼压(OU)升高24mmHg.在第三种情况下，1例46岁男性朗格汉斯细胞组织细胞增生症患者在开始使用cobimetinib治疗21天后出现新的IOP升高24mmHg.所有3名患者在给予多佐胺/噻吗洛尔后眼压恢复正常，并继续他们的癌症治疗。
■本报告介绍了服用三种不同MEK抑制剂的患者中3例IOP升高的病例，这表明在MEK抑制剂类别中存在IOP升高作用。所有3名患者对局部降压滴剂均有满意的反应，同时继续其维持生命的MEK抑制剂药物剂量，表明可能没有必要停止治疗。由于MEK抑制剂的使用越来越多，重要的是,眼科医生必须熟悉MEK抑制剂潜在的眼部不良反应的广泛范围.
■在第一种情况下，1例69岁女性转移性胆管癌患者,在开始曲美替尼治疗2个月后,其右眼眼压(OD)为25mmHg,左眼眼压(OS)为27mmHg.同样，在第二种情况下，1例26岁女性朗格汉斯细胞组织细胞增生症患者,在开始使用研究性MEK抑制剂治疗13个月后,双侧眼压(OU)升高24mmHg.在第三种情况下，1例46岁男性朗格汉斯细胞组织细胞增生症患者在开始使用cobimetinib治疗21天后出现新的IOP升高24mmHg.所有3名患者在给予多佐胺/噻吗洛尔后眼压恢复正常，并继续他们的癌症治疗。
■本报告介绍了服用三种不同MEK抑制剂的患者中3例IOP升高的病例，这表明在MEK抑制剂类别中存在IOP升高作用。所有3名患者对局部降压滴剂均有满意的反应，同时继续其维持生命的MEK抑制剂药物剂量，表明可能没有必要停止治疗。由于MEK抑制剂的使用越来越多，重要的是,眼科医生必须熟悉MEK抑制剂潜在的眼部不良反应的广泛范围.
